Pharma & Biotech: Hiring, Funding And Leadership Signals
Every update we hold from an employer we have filed under Pharma & Biotech: 914 updates from 77 sources, across 767 employers. Each one links to the filing or report that makes the claim. These are counts of documents we have read, so they measure what we have found and can cite, not everything that happened. They also include the routine officer filings the tracker sets aside by default, so its figure for this place is lower than the one above.
Covering 1 Jan 2026 to 14 Aug 2026
$10,347,872,751 disclosed across 304 funding updates. Totals cover the 290 of 304 funding updates that state a US dollar amount. We leave out amounts in other currencies rather than convert them at a rate nobody published.
Employers We Hold The Most On
Ranked by how many updates we hold, then by how many independent sources are behind them. That is a measure of our own coverage rather than of an employer's size. Each name links to everything we hold for that employer.
- Cingulate Inc. 5 updates
- Immunic, Inc. 4 updates
- Standard BioTools Inc. 4 updates
- Sanofi 3 updates
- GSK plc 3 updates
- Alkermes plc 3 updates
- NEONC TECHNOLOGIES HOLDINGS, INC. 3 updates
- Longeveron Inc. 3 updates
What The Updates Are About
Countries In This Industry
A name with a page of its own links to it. One we do not hold enough on for a page of its own links to the tracker filtered to it, which shows every update behind the count.
- United States 755 updates
- United Kingdom 25 updates
- Israel 16 updates
- Canada 15 updates
- India 9 updates
- France 8 updates
- Ireland 7 updates
- Switzerland 5 updates
Recent Updates
The 12 most recent, in the order the tracker itself uses. Every line links to the document it came from. See all 914 updates for Pharma & Biotech.
- 2026-08-14Headcount Not Stated Leadership moves
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring's leadership transition aligns the organization around focused advancement of the DUBLIN-4 program in NSCLC post-ICI.
- 2026-08-13Headcount Not Stated Growing and expanding
Khartis Therapeutics Raises $50M To Advance Oral Immunology Drugs
Khartis Therapeutics raised $50M in Series B for oral immunology drugs. The announcement does not disclose hiring plans; watch its careers page for pharma and biotech roles.
- 2026-08-11Headcount Not Stated Leadership moves
Bicara Therapeutics Announces Strategic Leadership Transitions
Bicara Therapeutics transitions executive leadership in Boston, with Ryan Cohlhepp becoming CEO and Claire Mazumdar moving to Vice Chair of the Board, effective January 2027.
- 2026-08-10Headcount Not Stated Growing and expanding
Replimune bondit après une levée de fonds de 150 millions de dollars pour un médicament contre le cancer de la
Replimune raised $150M for cancer-drug development in the US. The announcement does not disclose hiring plans; watch its careers page for biotech roles.
- 2026-08-10Headcount Not Stated Growing and expanding
Prana Therapies, Inc. raised $40.2M in a private placement
Prana Therapies has $40.2M of new capital in Encinitas. The filing does not disclose hiring plans; watch its careers page for biotech roles.
- 2026-07-31Adding Roles Ways of working
Resilience and Lilly invest $750M to scale Cincinnati medicine output
Resilience and Lilly's $750M investment to scale GLP-1 injectables manufacturing in Cincinnati creates 400 onsite manufacturing roles, concentrating pharma biotech hiring in contract production capacity rather than R&D.
- 2026-07-31Headcount Not Stated Leadership moves
XORTX Announces Director Resignation
Anthony Giovinazzo leaves the board of XORTX Therapeutics, a Calgary-based pharma and biotech firm.
- 2026-07-30Headcount Not Stated Growing and expanding
Ractigen Therapeutics Raises Over $31M in Funding
Ractigen Therapeutics has $31M of new capital. The announcement does not disclose hiring plans; watch its careers page for pharma and biotech roles.
- 2026-07-30Headcount Not Stated Growing and expanding
J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech
Johnson & Johnson is paying $785 million upfront for an option to buy Flagship's in vivo CAR-T biotech Sail Biomedicines, expanding its cell therapy pipeline, but the announcement names no hiring plans.
- 2026-07-29Headcount Not Stated Ways of working
GSK announces plan to axe UK Stevenage R&D hub, moving to Cambridge
GSK is closing its Stevenage R&D hub and relocating operations to Cambridge, affecting research roles in the UK.
- 2026-07-29Headcount Not Stated Growing and expanding
LB Pharmaceuticals capta US$ 150 milhões em esforços restritos
LB Pharmaceuticals raised US$150 million in a restricted offering for pharma and biotech development, a stage where funds typically flow into research and development headcount. The announcement does not disclose hiring plans.
- 2026-07-29Headcount Not Stated Growing and expanding
Core Biomedicine Raises $21M Series A to Advance Precision Oncology Pipeline
Core Biomedicine raised $21M in Series A funding to advance its precision oncology pipeline in pharma and biotech, a stage where headcount goes into research and development. The announcement names no roles.
The read-through on each line is our interpretation. The headline and figures come from the linked source. Data licensed CC BY 4.0. Every country, city and industry we cover · Every source · Back to the tracker